The U.S. Supreme Court is currently deliberating on a bankruptcy deal involving Purdue Pharma, the company held responsible for the opioid crisis in America. The deal, which would grant immunity to the Sackler family, who owned and controlled Purdue Pharma, in exchange for a $6 billion settlement, has sparked controversy and opposition.
The Sackler family's immunity would shield them from civil prosecution, a point of contention for several states, Canadian municipalities, Indigenous tribes, and individuals. Critics argue that the deal prevents the Sacklers from being held accountable for their actions.
The Biden administration has also voiced opposition to the deal, stating that it allows the Sacklers to avoid testifying about their alleged misdeeds and retain a significant portion of their assets. However, the plan has garnered the support of over 95% of the victims who brought lawsuits against Purdue Pharma.
The Supreme Court justices are reportedly torn over the settlement. They are keen to ensure justice for the victims and have expressed little sympathy for the Sackler family, who profited from the sale of the highly addictive painkiller, OxyContin.
Families impacted by the opioid crisis are divided on the deal. Some support it for the compensation it offers, while others oppose it, demanding that the Sacklers be held accountable. The court's decision is eagerly awaited as it will have significant implications for the victims of the opioid crisis and the future of Purdue Pharma.